AstraZeneca, Daiichi Sankyo eye first approval for TROP2 drug after PhIII breast cancer success
AstraZeneca and Daiichi Sankyo’s TROP2-targeted antibody-drug conjugate has met a key endpoint in the Phase III TROPION-Breast01 trial, bringing it one step closer to potentially compete against Gilead’s Trodelvy.
TROPION-Breast01 is evaluating the drug candidate, dato-DXd, against investigators’ choice of chemotherapy in 733 patients with previously-treated inoperable or metastatic HR-positive, HER2-negative breast cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.